| The
present study indicates the clinical, haematological and biochemical efficacy
of the herbal EazMov in the treatment of Osteoarthritis, non specific arthritis
and Rheumatoid arthritis. The immunomodulatory activity of EazMov could alter
the immunopathological processes rapidly. There was a definite improvement in
parameters like severity of pain, morning stiffness, Ritchie Articular Index,
grip strength, disability score etc. Safety profile and both hematological and
biochemical parameters as well as Ritchie Articular index showed better effects
with EazMov than Diclofenac.
Biswas et.
al. AIIMS. New Delhi, Presented at APICON-98, Bangalore, 16-20 Jan.98. The Indian
Journal of Clinical Pharmacology & Therapeutics, 18(4), Oct-Dec. 1997: 92.
Biochemical
and haematological examination of the human volunteers provided evidence for safety
of the product on liver and heamopoietic system. EazMov increased the total leukocyte
count and significantly reduced the ESR particularly of those who showed higher
pre-treatment value. EazMov can be used clinically as an anti-arthritic agent
quite safely without any toxic reaction in human subjects.
Ajay
Jain et. al.Indian J. Indg. Med. 19(1):83-87
Chronic
toxicity study of EazMov revealed the nontoxic nature of the product. EazMov did
not produce any heamopoietic, renal or hepatic toxicity. Thorough examination
of mucous surface of stomach did not show any lesions viz ulcer or haemorrhage.
EazMov was well tolerated on prolonged (90 days) administration and found to be
safe and non-ulcerogenic.
Das and Chatterjee,
Indian J.Indg.Med. 19(2): 152-158
In
this randomised, parallel clinical trial in patients of either sex with active
Rheumatoid arthritis with positive RA factor lgM baseline value 104 ± 42
of 1 to 4 years duration, both EazMov Plus and Chloroquine produced significant
decrease in rheumatoid factor between 27% to 32% as well as decrease in ESR with
highly significant (p < 0.001)response rate as per American college of Rheumatology
response criteria. Compared with baseline there was a significant decrease in
symptoms score, joint count and swollen joint count at the end of 12 and 24 weeks
and a marked decrease in duration of morning stiffness at the end of 24 weeks
treatment with EazMov Plus or Chloroquine while there was no change with placebo.
EazMov Plus exhibited higher safety profile.
Usha
Rani, P. (2005), Deptt. of Clinical Pharmacology & Therapeutics, Nizam's Institute
of Medical Sciences, Hyderabad. PaperPublished in Phytomedica 2006, 7:1-7 Efficacy
comparison of EazMov Plus and Ibuprofen with sex weeks treatment | Parameter | Ibuprofen | EazMov
Plus | Baseline
value | After 6 weeks value
| Baseline value | After
6 weeks value | | Pain
Index | 1.63 ±
0.5 | 1.13 ±
0.35* | 1.57 ±
0.51 | 1.12 ±
0.33* | | Swelling Index | 1.47
± 0.51 | 0.87
± 0.52** | 1.38
± 0.5 | 0.82
± 0.53*** | | Lequesne's
Index | 11.0 ±
2.24 | 8.97 ±
2.16** | 11.0 ±
2.34 | 8.74 ±
1.86*** | | VAS Score
(mm) | 61.8 ±
14 | 39.7 ±
17.9*** | 65.5 ±
12.8 | 40.6 ±
16.9*** | | Degree of
Flexion | 111 ±
9.47 | 120 ±
8.24** | 107 ±
7.68 | 119 ±
6.74*** |
P
value as compared to baseline (paired't' test):_________________
* = p<0.05 **=p<0.01 ***=p<0.001 Boswellic
acids inhibit the leukotriene biosynthesis by noncompetitive inhibition of 5-lipoxygenase
without affecting the 12-lipoxygenase and cycloxygenase activities, by their binding
to the enzyme and inhibiting elastase in leukocytes. In clinical trials promising
results were observed in patients with rheumatoid arthritis. In
a randomized double blind placebo controlled crossover study, all patients of
knee osteorthritis reported decrease in pain and swelling in the knee joint and
increase in knee flexion and walking distance. The observed differences between
drug treated and placebo being statistically significant.
Ammon
HP (2002). Wien Med. Wochenschr. 152: 373-378.
Kimmatkar
N,Thawani V, Hingorani L, Khiyani R (2003). Efficacy and tolerability of Boswellia
serrata extract in treatment of osteoarthritis of knee-a randomized double blind
placebo controlled trial. Phytomedicine. 10 : 3-7.
The
study was conducted to assess the efficacy of EazMov in comparison to diclofenac
in a double blind randomized comparative parallel design model. There was a definite
improvement from pre-to post-treatment status in all the parameters like severity
of pain, morning stiffness, Ritchie Articular Index, grip strength, disability
score etc. in patients of osteoarthritis, rheumatoid arthritis and non-specific
arthritis. However, clinical efficacy of diclofenac was better for severity of
pain and disability score only, though not statistically significant. Safety profile
and both hematological and biochemical parameters as well as Rithie Articular
Index showed better effects with EazMov than diclofenac.
Biswas,
NR (1998). A.I.I.M.S., New Delhi. J.K.Practitioner 5(2) : 129-132. | 